scholarly article | Q13442814 |
P50 | author | Eugene Braunwald | Q322114 |
Elliott M Antman | Q64496972 | ||
John Brandt | Q87611018 | ||
Marc S Sabatine | Q89851175 | ||
Jessica L. Mega | Q114341315 | ||
Stephen D Wiviott | Q114427160 | ||
Sandra L Close | Q114444050 | ||
Richard D Hockett | Q114444051 | ||
William L Macias | Q114444052 | ||
P2093 | author name string | Lei Shen | |
Joseph R Walker | |||
P433 | issue | 19 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | pharmacokinetics | Q323936 |
pharmacodynamics | Q725307 | ||
P304 | page(s) | 2553-2560 | |
P577 | publication date | 2009-05-04 | |
P1433 | published in | Circulation | Q578091 |
P1476 | title | Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes | |
P478 | volume | 119 |
Q37965481 | 2011 ACCF/AHA focused update of the guidelines for the management of patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 Guideline): highlights for the clinician. |
Q57774051 | A Risk–Benefit Assessment of Prasugrel, Clopidogrel, and Genotype-Guided Therapy in Patients Undergoing Percutaneous Coronary Intervention |
Q64882378 | A brief review on resistance to P2Y12 receptor antagonism in coronary artery disease. |
Q34150640 | A case of resistance to clopidogrel and prasugrel after percutaneous coronary angioplasty. |
Q37788682 | A comparison of the metabolism of clopidogrel and prasugrel |
Q37973114 | A comprehensive comparative review of adenosine diphosphate receptor antagonists |
Q54183735 | A randomized controlled trial of adjunctive Bunchang Naoxintong Capsule (步长脑心通胶囊) versus maintenance dose clopidogrel in patients with CYP2C19*2 polymorphism. |
Q37908891 | A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application? |
Q89064053 | A trial of type 12 purinergic (P2Y12) receptor inhibition with prasugrel identifies a potentially distinct endotype of patients with aspirin-exacerbated respiratory disease |
Q57764209 | ANMCO/SICI-GISE paper on antiplatelet therapy in acute coronary syndrome |
Q37998114 | Acute coronary syndromes: considerations for improved acceptance and implementation of management guidelines |
Q36807413 | Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelor |
Q38958862 | Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors |
Q34577974 | An algorithm for use of prasugrel (effient) in patients undergoing cardiac catheterization and percutaneous coronary intervention. |
Q47231767 | Analysis of CYP2C19 Genetic Polymorphism in a Large Ethnic Hakka Population in Southern China |
Q38106501 | Antiplatelet and anticoagulant strategies in acute coronary syndrome: where we are in 2013. |
Q26824701 | Antiplatelet and anticoagulation therapy for acute coronary syndromes |
Q33948811 | Antiplatelet drug interactions with proton pump inhibitors |
Q37882712 | Antiplatelet drug therapy: role of pharmacodynamic and genetic testing |
Q37738868 | Antiplatelet drugs--do we need new options? With a reappraisal of direct thromboxane inhibitors |
Q37684794 | Antiplatelet therapies for the treatment of cardiovascular disease |
Q37798110 | Antiplatelet therapy in acute coronary syndromes |
Q36160606 | Antiplatelet therapy in acute coronary syndromes: current agents and impact on patient outcomes |
Q35660184 | Antithrombotic therapy in patients with acute coronary syndromes: a balance between protection from ischemic events and risk of bleeding. |
Q42907062 | Antithrombotics in acute coronary syndromes: updates from the past year. |
Q38132923 | Assessing post-treatment platelet reactivity: a focus on patient selection and setting. |
Q37683552 | Balancing the benefits and risks of antiplatelet agents in patients with non-ST-segment elevated acute coronary syndromes and undergoing percutaneous coronary intervention |
Q92263864 | Between a rock and a hard place: a high-risk patient with resistance to multiple P2Y12 antagonists |
Q37831317 | Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor. |
Q38073672 | CYP-mediated pharmacologic interference with optimal platelet inhibition |
Q90217107 | CYP2C19*17 May Increase the Risk of Death Among Patients with an Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Who Receive Clopidogrel and Rivaroxaban |
Q89585264 | CYP3A4*22 Impairs the Elimination of Ticagrelor, But Has No Significant Effect on the Bioactivation of Clopidogrel or Prasugrel |
Q36696635 | Cardiovascular Pharmacogenomics--Implications for Patients With CKD. |
Q38220502 | Cardiovascular drugs and the genetic response. |
Q35447163 | Cardiovascular pharmacogenomics |
Q38169969 | Cardiovascular pharmacogenomics: expectations and practical benefits |
Q38106616 | Challenges and limitations in the interpretation of systematic reviews: making sense of clopidogrel and CYP2C19 pharmacogenetics. |
Q86202099 | Circulating reticulated platelets over time in patients with myocardial infarction treated with prasugrel or ticagrelor |
Q88258320 | Clinical Outcomes and Sustainability of Using CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention |
Q37107608 | Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. |
Q35603072 | Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy |
Q98612878 | Clinical Utility of CYP2C19 Genotype-Guided Antiplatelet Therapy in Patients at Risk of Adverse Cardiovascular and Cerebrovascular Events: A Review of Emerging Evidence |
Q26849254 | Clinical application of cardiovascular pharmacogenetics |
Q37970334 | Clinical considerations of heritable factors in common heart failure |
Q35033722 | Clinical evidence of interaction between clopidogrel and proton pump inhibitors |
Q38059616 | Clinical impact of genetically determined platelet reactivity |
Q52593402 | Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention. |
Q38177048 | Clinical implications of drug-drug interactions with P2Y12 receptor inhibitors |
Q34390050 | Clinical importance of aspirin and clopidogrel resistance |
Q33825186 | Clinical pharmacogenetics implementation: approaches, successes, and challenges |
Q51530037 | Clinical predictors of high posttreatment platelet reactivity to clopidogrel in Koreans. |
Q93175682 | Clopidogrel Pharmacogenetics |
Q50867606 | Clopidogrel Resistance in Neurovascular Stenting: Correlations between Light Transmission Aggregometry, VerifyNow, and the Multiplate. |
Q42961054 | Clopidogrel and proton pump inhibitors: between a rock and a hard place |
Q38830015 | Clopidogrel pharmacogenetics: from evidence to implementation |
Q37627874 | Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations |
Q38128171 | Clopidogrel, prasugrel, or ticagrelor? a practical guide to use of antiplatelet agents in patients with acute coronary syndromes |
Q41141258 | Clopidogrel: a pharmacogenomic perspective on its use in coronary artery disease |
Q30573045 | Clopidogrel: the data, the experience, and the controversies |
Q38008466 | Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications |
Q37629641 | Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention. |
Q91738100 | Comparison of prasugrel and clopidogrel in patients with non-cardioembolic ischaemic stroke: a phase 3, randomised, non-inferiority trial (PRASTRO-I) |
Q37774825 | Considerations in patients receiving oral antiplatelet therapy after acute coronary syndrome and percutaneous coronary intervention |
Q91063306 | Cost-effectiveness analysis of pharmacogenomics-guided clopidogrel treatment in Spanish patients undergoing percutaneous coronary intervention |
Q89637477 | Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data |
Q37445540 | Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel |
Q45815157 | Cost-effectiveness of using CYP2C19 genotype to guide selection of clopidogrel or ticagrelor in Australia |
Q34166239 | Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary intervention |
Q35660767 | Critical appraisal of ticagrelor in the management of acute coronary syndrome |
Q38362982 | Current antiplatelet agents: place in therapy and role of genetic testing |
Q34382431 | Current concepts on antiplatelet therapy: focus on the novel thienopyridine and non-thienopyridine agents |
Q58694656 | Dental management of patients on anti-thrombotic agents |
Q41848961 | Determinants to optimize response to clopidogrel in acute coronary syndrome |
Q39142325 | Development of a broad-based ADME panel for use in pharmacogenomic studies |
Q53200993 | Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: Which Regimen and for How Long? |
Q34622955 | Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial |
Q42632671 | Effect of age on the pharmacokinetics and pharmacodynamics of prasugrel during multiple dosing: an open-label, single-sequence, clinical trial |
Q35846138 | Effect of grapefruit juice on the bioactivation of prasugrel |
Q37807398 | Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel |
Q38023512 | Effects of VerifyNow P2Y12 test and CYP2C19*2 testing on clinical outcomes of patients with cardiovascular disease: a systematic review and meta-analysis |
Q34352152 | Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease |
Q60310000 | Effects of switching ticagrelor to clopidogrel on cardiovascular outcomes in patients with acute coronary syndrome |
Q37685847 | Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist |
Q37979178 | Emerging antiplatelet agents, differential pharmacology, and clinical utility |
Q37670190 | Emerging drugs for acute myocardial infarction |
Q37949587 | Emerging therapies for acute coronary syndromes |
Q51749154 | Evaluation of the INNOVANCE PFA P2Y assay and its association with CYP2C19 genotypes. |
Q38098452 | Expanding role of pharmacogenomics in the management of cardiovascular disorders |
Q37497555 | Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. |
Q57794673 | Frequencies of poor metabolizer alleles of 12 pharmacogenomic actionable genes in Punjabi Sikhs of Indian Origin |
Q91969049 | Frequency and clinical outcomes of CYP2C19 genotype-guided escalation and de-escalation of antiplatelet therapy in a real-world clinical setting |
Q30359686 | Future translational applications from the contemporary genomics era: a scientific statement from the American Heart Association |
Q43158045 | Genetic CYP2C19 polymorphism dependent non-responders to clopidogrel therapy--does structural design, dosing and induction strategies have a role to play? |
Q88842612 | Genetic Determinants of P2Y12 Inhibitors and Clinical Implications |
Q37991382 | Genetic and non-genetic factors affecting the response to clopidogrel therapy. |
Q37697779 | Genetic causes of clopidogrel nonresponsiveness: which ones really count? |
Q37989811 | Genetic determinants of response to cardiovascular drugs |
Q34633385 | Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy |
Q33988457 | Genetic regulation of platelet receptor expression and function: application in clinical practice and drug development |
Q44258281 | Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis |
Q34564576 | Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis |
Q38131848 | Genetics of platelet inhibitor treatment |
Q34109838 | Genomics in coronary artery disease: past, present and future |
Q37907918 | Genotypic and phenotypic assessment of platelet function and response to P2Y12 antagonists |
Q41432957 | Genotyping of CYP2C19 polymorphisms and its clinical validation in the ethnic Arab population |
Q33863833 | Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group |
Q38104273 | High prevalence of CYP2C19*2 allele in Roma samples: study on Roma and Hungarian population samples with review of the literature |
Q35109254 | Humanizing thrombi in mice |
Q46319910 | Identification of PEAR1 SNPs and their influences on the variation in prasugrel pharmacodynamics |
Q37203987 | Impact of Cytochrome P450 2C19*2 and *3 on Clopidogrel Loading Dose in Saudi Patients with Acute Coronary Syndrome |
Q42757370 | Impact of genetic polymorphisms in the clinical response of oral inhibitors of the platelet P2Y12 adenosine diphosphate (ADP) receptor |
Q36441477 | Impact of genetic polymorphisms on clinical response to antithrombotics |
Q64948132 | Impact of genetic polymorphisms on platelet function and response to anti platelet drugs. |
Q26745754 | Impact of selective platelet inhibition in reducing cardiovascular risk - role of vorapaxar |
Q99210892 | Impact of the CYP2C19*17 allele on outcomes in patients receiving genotype-guided antiplatelet therapy after percutaneous coronary intervention |
Q50940254 | Implementation and evaluation of a CYP2C19 genotype-guided antiplatelet therapy algorithm in high-risk coronary artery disease patients. |
Q54374494 | Implementation of inpatient models of pharmacogenetics programs. |
Q33990428 | Implementing genotype-guided antithrombotic therapy |
Q34981428 | Indirect estimation of the comparative treatment effect in pharmacogenomic subgroups |
Q44986245 | Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease |
Q38071262 | Influence of platelet reactivity on clinical outcome of patients with stable coronary artery disease. |
Q34174915 | Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes |
Q33561577 | Integrated analysis of pharmacokinetic data across multiple clinical pharmacology studies of prasugrel, a new thienopyridine antiplatelet agent |
Q38012079 | Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention |
Q37679719 | Limitations of current therapies to prevent thrombosis: a need for novel strategies |
Q38476938 | Management of Coronary Artery Disease in South Asian Populations: Why and How to Prevent and Treat Differently |
Q47658855 | Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention |
Q48345994 | Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy. |
Q37768334 | New antithrombotic agents--insights from clinical trials |
Q38257119 | Novel antiplatelet agents in acute coronary syndrome |
Q33902628 | Novel antiplatelet agents in the prevention of cardiovascular complications--focus on ticagrelor |
Q37880741 | Optimizing antiplatelet therapy in acute coronary syndrome and percutaneous coronary intervention |
Q35141772 | Oral antiplatelet therapy in diabetes mellitus and the role of prasugrel: an overview |
Q37762149 | Overcoming 'resistance' to antiplatelet therapy: targeting the issue of nonadherence |
Q33853179 | Pantoprazole Does Not Reduce the Antiplatelet Effect of Clopidogrel: A Randomized Controlled Trial in Korea |
Q58804403 | Percutaneous pleural drainage in patients taking clopidogrel: real danger or phantom fear? |
Q26822796 | Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics |
Q37877165 | Personalized antiplatelet therapy: review of the latest clinical evidence |
Q41960992 | Personalized healthcare in clotting disorders |
Q38682772 | Personalizing antiplatelet prescribing using genetics for patients undergoing percutaneous coronary intervention |
Q38040698 | Personalizing antiplatelet therapy with clopidogrel. |
Q37590925 | Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials |
Q38018679 | Pharmacodynamic properties of antiplatelet agents: current knowledge and future perspectives |
Q44877659 | Pharmacogenetic Analysis of the Model-Based Pharmacokinetics of Five Anti-HIV Drugs: How Does This Influence the Effect of Aging? |
Q34161006 | Pharmacogenetics and clopidogrel response in patients undergoing percutaneous coronary interventions. |
Q37924323 | Pharmacogenetics and pharmacogenomics of thienopyridines: clinically relevant? |
Q37583599 | Pharmacogenetics and safety parameters for platelet P2Y12 receptor antagonists |
Q37808224 | Pharmacogenetics guided anticoagulation |
Q38148597 | Pharmacogenetics of antiplatelets and anticoagulants: a report on clopidogrel, warfarin and dabigatran. |
Q23919667 | Pharmacogenetics, pharmacogenomics, and individualized medicine |
Q64890735 | Pharmacogenomic considerations for antiplatelet agents: the era of precision medicine in stroke prevention and neurointerventional practice. |
Q26997380 | Pharmacogenomics and cardiovascular disease |
Q89890370 | Pharmacogenomics in Asian subpopulations and impacts on commonly prescribed medications |
Q38117748 | Pharmacogenomics in cardiovascular disease: focus on aspirin and ADP receptor antagonists |
Q37933413 | Pharmacogenomics in the assessment of therapeutic risks versus benefits: inside the United States Food and Drug Administration |
Q38195628 | Pharmacogenomics of oral antiplatelet drugs. |
Q34976915 | Pharmacogenomics: the genetics of variable drug responses |
Q37927151 | Pharmacokinetic basis of the antiplatelet action of prasugrel |
Q35640465 | Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants |
Q38154211 | Pharmacology of antiplatelet agents |
Q38151563 | Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties. |
Q41052640 | Platelet Aggregation Inhibitory Effects and Pharmacokinetics of Prasugrel Used in Combination With Aspirin in Healthy Japanese Subjects |
Q38007894 | Platelet function and inhibition in ischemic heart disease |
Q38233284 | Platelet function inhibitors and platelet function testing in neurointerventional procedures. |
Q38094681 | Platelet function testing and tailored antiplatelet therapy |
Q38132252 | Platelet reactivity tests for assessing antiplatelet drug response: what the clinician needs to know |
Q34264876 | Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial |
Q33818356 | Potential Usefulness of Clopidogrel Pharmacogenetics in Cerebral Endovascular Procedures and Carotid Artery Stenting. |
Q37818331 | Prasugrel for the treatment of coronary thrombosis: a review of pharmacological properties, indications for use and future development |
Q38336838 | Prasugrel hydrochloride for the treatment of acute coronary syndromes. |
Q38012439 | Prasugrel is effective and safe for neurointerventional procedures |
Q43261109 | Prasugrel or clopidogrel in patients with coronary intervention |
Q37905028 | Prasugrel resistance: fact or fiction |
Q37982427 | Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients |
Q43430172 | Prasugrel versus high dose clopidogrel to overcome early high on clopidogrel platelet reactivity in patients with ST elevation myocardial infarction. |
Q33584173 | Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data |
Q37579188 | Prasugrel: a review of its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention |
Q38007860 | Pre PCI hospital antithrombotic therapy for ST elevation myocardial infarction: striving for consensus |
Q36210219 | Predicting inhaled corticosteroid response in asthma with two associated SNPs |
Q44474790 | Prediction of prasugrel active metabolite concentrations from 2 downstream inactive metabolite concentrations using multilinear regression analysis |
Q39622468 | Prophylactic Antiplatelet Medication in Endovascular Treatment of Intracranial Aneurysms: Low-Dose Prasugrel versus Clopidogrel |
Q44999184 | Proton-pump inhibitors in patients requiring antiplatelet therapy: new FDA labeling |
Q64903262 | Rationale, Design, and Baseline Characteristics of the Prospective Japan Acute Myocardial Infarction Registry (JAMIR). |
Q34131354 | Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice |
Q38216600 | Recent advances in antithrombotic treatment for acute coronary syndromes. |
Q37972231 | Recent advances in the pharmacogenetics of clopidogrel |
Q37289886 | Reduced number of cardiovascular events and increased cost-effectiveness by genotype-guided antiplatelet therapy in patients undergoing percutaneous coronary interventions in the Netherlands |
Q34624862 | Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis |
Q37693951 | Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis. |
Q37799470 | Review article: combination of clopidogrel and proton pump inhibitors: implications for clinicians |
Q38347110 | Review of pharmacoeconomic evaluation of genotype-guided antiplatelet therapy. |
Q38401281 | Role of Genetic Testing in Patients undergoing Percutaneous Coronary Intervention |
Q36441521 | Role of cytochrome P450 genotype in the steps toward personalized drug therapy |
Q38048837 | Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y₁₂ receptor inhibitors |
Q34990721 | Routine screening for CYP2C19 polymorphisms for patients being treated with clopidogrel is not recommended |
Q60018207 | Résistance au clopidogrel, tests génétiques et tests fonctionnels |
Q44483899 | Safe and effective medicines for all: is personalized medicine the answer? |
Q53704317 | Safety of Prasugrel loading in ruptured blister like aneurysm treated with a Pipeline device. |
Q38209661 | Significance of antiplatelet therapy in emergency myocardial infarction treatment |
Q41651465 | Significant Improvement of Antithrombotic Responses to Clopidogrel by Use of a Novel Conjugate as Revealed in an Arterial Model of Thrombosis |
Q38970275 | Single or dual antiplatelet therapy after PCI. |
Q37697014 | State of the art of new P2Y12 antagonists. |
Q83117953 | Stent thrombosis: understanding and managing a critical problem |
Q35015993 | Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. |
Q37925009 | TRITON and beyond: new insights into the profile of prasugrel |
Q40498149 | Tailored Thienopyridine therapy: no urgency for CYP2C19 genotyping |
Q42204185 | The Affymetrix DMET Plus platform reveals unique distribution of ADME-related variants in ethnic Arabs |
Q37462239 | The Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Japanese Volunteers |
Q40157153 | The association between CYP2C19 genotype and of in-stent restenosis among patients with vertebral artery stent treatment |
Q84968912 | The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: a New Zealand evaluation |
Q51816112 | The discovery and development of prasugrel. |
Q38053481 | The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. |
Q38750444 | The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban). |
Q38603459 | The impact of switching P2Y12 receptor inhibitor therapy during index hospitalization: a systematic review |
Q35683944 | The interaction between clopidogrel and proton pump inhibitors (PPI): is there any clinical relevance? |
Q100504013 | The need of a multicomponent guiding approach to personalize clopidogrel treatment |
Q26801867 | The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19 |
Q37913976 | The pharmacogenetics of antiplatelet agents: towards personalized therapy? |
Q38003702 | The pharmacogenomics of sex hormone metabolism: breast cancer risk in menopausal hormone therapy |
Q84443544 | The promises of personalized medicine |
Q37576116 | Thienopyridine therapy and risk for cardiovascular events in secondary prevention |
Q37914050 | Thienopyridine-associated drug-drug interactions: pharmacologic mechanisms and clinical relevance |
Q41817424 | Towards personalized medicine based on platelet function testing for stent thrombosis patients |
Q34608705 | Understanding the economic value of molecular diagnostic tests: case studies and lessons learned |
Q37972109 | Unstable angina and non-ST elevation myocardial infarction |
Q28553219 | Up-Regulation of CYP2C19 Expression by BuChang NaoXinTong via PXR Activation in HepG2 Cells |
Q38161394 | Updates in antiplatelet agents used in cardiovascular diseases |
Q30978916 | Use of genetic data to guide therapy in arterial disease |
Q37936014 | Variability of clopidogrel response in patients with type 2 diabetes mellitus |
Q43049704 | Voluntary exploratory data submissions to the US FDA and the EMA: experience and impact |
Q38355060 | Vorapaxar in atherosclerotic disease management |
Q37704842 | What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel |
Q87450358 | [ENT surgery in patients with anticoagulants and platelet aggregation inhibitors] |
Q83592968 | [Periinterventional antiplatelet therapy: from bench to bedside] |
Q26829973 | 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Associat |
Search more.